Alkermes plc
ALKS
Rankning i aktier
#2726
Alkermes plc, a biopharmaceutical company, engages in the research,... Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Aktiekurs
$41.39
Senast synkroniserad: 2026-10-16
Marknadsvärde
$6.94B
Förändring (1 dag)
3.22%
Förändring (1 år)
36.78%
Land
IE
Handel Alkermes plc (ALKS)
Kategori
Healthcare
EPS för Alkermes plc (ALKS)
EPS per June 2026 TTM: $0.40
Enligt Alkermes plcs senaste finansiella rapporter och aktiekurs är bolagets nuvarande EPS (TTM) $0.40. Vid slutet av 2023 hade bolaget ett EPS på $2.14, en ökning jämfört med EPS från 2022 som var $-0.97.
EPS-historik för Alkermes plc från 2000 till 2026
EPS vid slutet av varje år
| År | EPS | Ändra |
|---|---|---|
| 2026 (TTM) | $0.40 | -81.98% |
| 2024 | $2.22 | 3.74% |
| 2023 | $2.14 | -320.62% |
| 2022 | $-0.97 | 223.33% |
| 2021 | $-0.30 | -57.14% |
| 2020 | $-0.70 | -44.00% |
| 2019 | $-1.25 | 38.89% |
| 2018 | $-0.90 | -12.62% |
| 2017 | $-1.03 | -25.36% |
| 2016 | $-1.38 | -9.21% |
| 2015 | $-1.52 | 623.81% |
| 2014 | $-0.21 | -210.53% |
| 2013 | $0.19 | 0.00% |
| 2012 | $0.19 | -119.19% |
| 2011 | $-0.99 | 106.25% |
| 2010 | $-0.48 | 14.29% |
| 2009 | $-0.42 | -130.66% |
| 2008 | $1.37 | -17.47% |
| 2007 | $1.66 | 1,560.00% |
| 2006 | $0.10 | 150.00% |
| 2005 | $0.04 | -104.82% |
| 2004 | $-0.83 | -33.60% |
| 2003 | $-1.25 | -26.47% |
| 2002 | $-1.70 | 77.08% |
| 2001 | $-0.96 | 123.26% |
| 2000 | $-0.43 | 0.00% |
EPS för liknande företag eller konkurrenter
| Företag | EPS | EPS-differens | Land |
|---|---|---|---|
| $17.32 | 4,230.00% |
US
|
|
| $-7.98 | -2,095.00% |
US
|
|
| $-5.29 | -1,422.50% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | 6,835.00% |
NL
|
